🧠 PD-1 vs PD-L1 — Never Confuse Them Again! 🎯 Easy Memory Trick: 👮 PD-1 = Police (T Cell) 🦠 PD-L1 = People (Tumor Cell) Think of the T cell as a police officer fighting cancer. ✅ PD-1 is the inhibitory receptor on activated T lymphocytes. ✅ PD-L1 is the ligand expressed on tumor cells, APCs, and stromal cells. ✅ When PD-L1 binds PD-1, the immune response is switched off, allowing tumor immune escape. 💡 High-Yield Exam Pearl: “Receptors stay on T cells, ligands stay on tumor/APC cells.” Remember: 🔹 PD-1 = Player 1 = T Cell 🔹 PD-L1 = Lying Tumor = Tumor Cell A simple concept that forms the basis of modern cancer immunotherapy! #MedicalOncology #Immunotherapy #PD1 #PDL1 #CheckpointInhibitors #CancerImmunotherapy #OncologyEducation #MedEd #FOAMed #NEETSS #DrNBOncology #DMOncology #ASCO #ESMO #CancerConceptsExplained #OncologyResidents #MedicalEducation #HematologyOncology #CancerResearch #LearningMadeEasy

“📊 Adjuvant Treatment After Upfront Surgery in Upper Tract Urothelial Carcinoma (UTUC) After radical nephroureterectomy (RNU) for high-risk localized UTUC, adjuvant platinum-based chemotherapy is now standard of care (pT2–T4 or pN+ disease) — driven by the landmark POUT trial. ✅ Preferred: Gemcitabine + Cisplatin ✅ If cisplatin-ineligible (very common post-RNU due to sharp GFR drop): Gemcitabine + Carboplatin Key nuance unique to UTUC (unlike bladder cancer): In bladder urothelial carcinoma, cisplatin remains strongly preferred and carboplatin is generally suboptimal. But in UTUC, nephroureterectomy often renders patients cisplatin-ineligible — making Gem + Carbo a practical and evidence-based alternative here. Always reassess renal function post-RNU. Consider neoadjuvant chemo preoperatively whenever feasible (kidneys still intact!). Full practical guide + clinical pearls in the infographic 👇 #UTUC #UrothelialCarcinoma #BladderCancer #MedOnc #UroOnc #CancerCare @DrRupamOncology”

🌸 Maintenance Treatment in Ovarian Cancer – Curative Intent Approach Biomarker-driven (BRCA & HRD status) is now standard. Practical algorithm for Stage III–IV disease: • BRCA mutated → Olaparib (preferred) • HRD+ / BRCA wild-type → Niraparib OR Olaparib + Bevacizumab • HRD-negative → Bevacizumab continuation ± Niraparib (selected cases) Includes: ✅ Who needs maintenance ✅ Key trials (SOLO-1, PRIMA, PAOLA-1, GOG-0218) ✅ Durations, toxicities & clinical pearls ✅ Simplified exam-oriented flowchart PARP inhibitors have truly transformed outcomes in ovarian cancer! Save this visual guide & share with your trainees/colleagues 👇 #OvarianCancer #GynOnc #PARPInhibitors #PrecisionMedicine #Oncology #BRCA #HRD #CancerConceptsExplained Follow @DrRupamOncology for more evidence-based visuals! 💜

🚨 MATTERHORN Trial – New Standard Perioperative Chemo-Immunotherapy for Resectable Gastric/GEJ Adenocarcinoma! **Regimen (Experimental Arm):** Durvalumab 1500 mg IV Q4W + FLOT (Docetaxel 50 + Oxaliplatin 85 + Leucovorin 200 + 5-FU 2600 mg/m²) → **2 cycles neoadjuvant** (pre-surgery) → Surgery → **2 cycles adjuvant** (post-surgery) → **Durvalumab 1500 mg Q4W × 10 cycles maintenance** **Total:** 4 cycles FLOT + Durvalumab + 10 cycles Durvalumab alone **Total Durvalumab:** 14 cycles 📈 Key Results: • pCR nearly tripled: ~19% vs ~7% • EFS significantly improved (HR 0.71) • OS benefit confirmed • R0 resection & safety profile preserved Perioperative durvalumab + FLOT is now a new standard for HER2-negative resectable gastric/GEJ cancers. Full infographic breakdown 👇 #MATTERHORN #GastricCancer #GEJCancer #Immunotherapy #Oncology #ASCO #ESMO @DrRupamOncology

Supportive care is the backbone of successful multiple myeloma therapy. From neuropathy prevention with bortezomib to mandatory thromboprophylaxis with lenalidomide — proactive monitoring improves outcomes, adherence, and quality of life. 💉🩸🦴 A concise high-yield infographic for oncology trainees & clinicians. #MultipleMyeloma #Bortezomib #Lenalidomide #Hematology #MedicalOncology #Oncology #Myeloma #CancerEducation #OncologyNotes #MedEd #FOAMed #HemOnc #OncoTwitter #DrRupamManna

⚠️ Proton Pump Inhibitor (PPI) Contraindications & Important Interactions with Anticancer Drugs PPIs (pantoprazole, omeprazole, rabeprazole, esomeprazole) are extremely common in oncology patients, yet many oral targeted therapies require acidic gastric pH for optimal absorption. This practical infographic highlights: • High-risk interactions (Dasatinib, Erlotinib, Pazopanib, Acalabrutinib & more) • BTK inhibitors, Capecitabine, CDK4/6 inhibitors • Clinical impact & real-world consequences • Safer alternatives & management strategies • Key clinical pearls for daily practice Critical for every medical oncologist! Save | Share | Tag a colleague who needs this 👇 Made with ❤️ by Dr Rupam Manna Cancer Concepts Explained Follow for more → @DrRupamOncology #Oncology #DrugInteractions #TKI #PPI #MedEd #MedTwitter #CancerCare #CancerConceptsExplained

🚨 Landmark SOFT & TEXT Trials – Practice-Changing Insights for Premenopausal HR+ Early Breast Cancer Ovarian function suppression (OFS) + Exemestane is one of the most effective endocrine strategies in higher-risk patients. Risk-adapted therapy is key: ✅ Low-risk → Tamoxifen alone ✅ Young, node+, chemo-treated, high-grade → OFS + AI Maximal estrogen deprivation works. 15-year data confirms durable DFS & distant recurrence benefit. Full visual summary of trial designs, results, toxicities & guidelines in the infographic 👇 #BreastCancer #Oncology #SOFTTrial #TEXTTrial #EndocrineTherapy #HRPositive #PremenopausalBC #CancerResearch Follow for more evidence-based visuals → @DrRupamOncology

🧠 LEPTOMENINGEAL METASTASIS (LM) / LEPTOMENINGEAL CARCINOMATOSIS – High-Yield Overview LM is one of the most devastating complications of advanced cancer. Tumor cells spread to the leptomeninges + CSF, causing multifocal neurologic deficits involving the brain, cranial nerves, and spine simultaneously — a classic clinical clue! This infographic covers: ✅ What is LM & the leptomeninges ✅ Pathophysiology & why incidence is rising ✅ Most common cancers (Breast, Lung — esp. EGFR/ALK/SCLC, Melanoma) ✅ Clinical features (cerebral, cranial nerve, spinal) ✅ Diagnosis (MRI “sugar-coating”, CSF analysis, advanced testing) ✅ Prognosis ✅ Goals of treatment & major modalities (Systemic therapy, Intrathecal, Radiation, Supportive care, Ommaya reservoir) ✅ Emerging concepts & practical pearls Essential reading for every oncology trainee, fellow & practicing oncologist! #LeptomeningealMetastasis #LM #NeuroOncology #CancerConceptsExplained #OncologyEducation #MedicalOncology Follow for more high-yield visuals → @DrRupamOncology

📊 EMILIA Trial Summary – The landmark Phase III study that changed second-line treatment for HER2+ metastatic breast cancer forever! T-DM1 (Trastuzumab Emtansine / Kadcyla) vs Lapatinib + Capecitabine: ✅ PFS: 9.6 vs 6.4 months
✅ OS: 30.9 vs 25.1 months
✅ Better tolerability & quality of life This practice-changing trial established T-DM1 as the new global standard, proved the power of ADCs, and opened the modern era of “smart chemotherapy.” Full visual breakdown in the infographic 👇 #HER2 #BreastCancer #Oncology #T-DM1 #ADC #EMILIATrial #PrecisionMedicine Follow for more landmark trial summaries @DrRupamOncology

Neuroendocrine Tumors (NETs) — one-page mastery 🧬 From Ki-67 grading → classification → targeted therapy, this is the framework you need for both exams & clinics. 🔑 Remember: • Grade drives treatment • SSA = first-line (low-grade) • PRRT = game changer • NEC → treat like SCLC #MedicalOncology #NETs #Oncology #DrNB #DMOncology #OncoTwitter #MedEd #CancerEducation #PRRT #ExamPrep

🚨 Landmark Practice-Changing Trials in Prostate Cancer 🔥 From ADT alone → CHAARTED/STAMPEDE → ARASENS triplet → VISION PSMA therapy → the entire evolution of advanced prostate cancer in ONE high-yield infographic. Ultra-high-yield pearls every uro-oncologist & fellow needs: • ARASENS = new gold standard triplet in fit mHSPC • Avoid blind ARPI sequencing (CARD trial) • PSMA theranostics & PARP inhibitors now routine • Local RT still matters in low-volume mets (STAMPEDE) • Darolutamide preferred in elderly/comorbid nmCRPC The timeline every DM/DrNB candidate must know. Full infographic ↓ How has this changed your frontline approach in mHSPC/mCRPC? #ProstateCancer #mHSPC #mCRPC #UroOncology #Oncology #MedEd #CancerResearch #ARPI #PSMA

🧬 Acute Lymphoblastic Leukemia (ALL) – Treatment Simplified From induction to maintenance, ALL management is a multi-phase, MRD-guided strategy aiming for cure. 💡 Key pearls: ▪️ 4 phases = Induction → Consolidation → CNS prophylaxis → Maintenance ▪️ MRD = most important prognostic marker ▪️ Ph+ ALL → add TKI (Imatinib/Dasatinib) ▪️ CNS prophylaxis → ALL patients ▪️ R/R ALL → Blinatumomab, Inotuzumab, CAR-T 🚀 Modern therapy = high cure rates, especially in children #MedicalOncology #Hematology #ALL #Leukemia #OncologyEducation #MedEd #FOAMed #NeetSS #DrNB #MRCP #CancerCare #OncologyNotes #MedTwitter #DoctorLife

📌 High-Yield Preventive Oncology Every Oncologist & Resident Must Know **Surgery for Prevention of Hereditary Cancers** (Risk-Reducing / Prophylactic Surgery) Complete visual masterclass covering: ✅ BRCA1/2 → RRM + RRSO (timing & 90–95% risk reduction) ✅ Lynch Syndrome → Hysterectomy + BSO + Colectomy ✅ FAP → Total proctocolectomy + IPAA ✅ MEN2 → Prophylactic thyroidectomy (RET-based) ✅ CDH1 → Prophylactic gastrectomy ✅ Li-Fraumeni → Why surveillance is preferred Plus: Genetic counseling, fertility preservation, timing, complications & exam-ready table “Identify high-risk genes early → Intervene BEFORE cancer develops” Save it. Share it. Use it in clinic & viva. Next topic dropping soon: Endometrium Workup & Clinical Implications Dr Rupam Manna MD @DrRupamOncology #HereditaryCancer #RiskReducingSurgery #BRCA #LynchSyndrome #PreventiveOncology #SurgicalOncology #OncoViva #MedicalEducation #CancerPrevention